Cargando…

Prognostic Importance of Defibrillator‐Appropriate Shocks and Antitachycardia Pacing in Patients With Mild Heart Failure

BACKGROUND: Patients with heart failure and an implantable cardioverter‐defibrillator (ICD) for primary prevention are at increased mortality risk after receiving shock therapy. We sought to determine the prognostic significance of ICD therapies, both shock and antitachycardia pacing, delivered for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Biton, Yitschak, Daimee, Usama A., Baman, Jayson R., Kutyifa, Valentina, McNitt, Scott, Polonsky, Bronislava, Zareba, Wojciech, Goldenberg, Ilan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475071/ https://www.ncbi.nlm.nih.gov/pubmed/30857452 http://dx.doi.org/10.1161/JAHA.118.010346

Ejemplares similares

Need for pacing in patients who qualify for an implantable cardioverter‐defibrillator: Clinical implications for the subcutaneous ICD
por: Kutyifa, Valentina, et al.
Publicado: (2020)

Sex Differences in Long-Term Outcomes With Cardiac Resynchronization Therapy in Mild Heart Failure Patients With Left Bundle Branch Block
por: Biton, Yitschak, et al.
Publicado: (2015)

Implantable cardioverter-defibrillator programming after first occurrence of ventricular tachycardia in the Multicenter Automatic Defibrillator Implantation Trial–Reduce Inappropriate Therapy (MADIT-RIT)
por: Aktas, Mehmet K., et al.
Publicado: (2020)

Effect of obesity on the effectiveness of cardiac resynchronization to reduce the risk of first and recurrent ventricular tachyarrhythmia events
por: Szepietowska, Barbara, et al.
Publicado: (2016)

Outcome by Sex in Patients With Long QT Syndrome With an Implantable Cardioverter Defibrillator
por: Younis, Arwa, et al.
Publicado: (2020)

Primary prevention implantable cardioverter defibrillator in cardiac resynchronization therapy recipients with advanced chronic kidney disease
por: Goldenberg, Ido, et al.
Publicado: (2023)

Sex Differences in the Risk of First and Recurrent Ventricular Tachyarrhythmias Among Patients Receiving an Implantable Cardioverter-Defibrillator for Primary Prevention
por: Saxena, Shireen, et al.
Publicado: (2022)

Extended use of the wearable cardioverter-defibrillator in patients at risk for sudden cardiac death
por: Kutyifa, Valentina, et al.
Publicado: (2018)

Clinical presentation at first heart failure hospitalization does not predict recurrent heart failure admission
por: Kosztin, Annamaria, et al.
Publicado: (2017)

Risk factors for ventricular tachyarrhythmic events in patients without left bundle branch block who receive cardiac resynchronization therapy
por: Younis, Arwa, et al.
Publicado: (2021)

Antitachycardia pacing programming in implantable cardioverter defibrillator: A systematic review
por: De Maria, Elia, et al.
Publicado: (2017)

A Case of 25 Inappropriate Automatic Implantable Cardioverter Defibrillator Shocks and 22 Episodes of Antitachycardia Pacing
por: Morrison, Nathan, et al.
Publicado: (2023)

Unsuccessful antitachycardia pacing: What is the mechanism?
por: Strik, Marc, et al.
Publicado: (2019)

Assessment of absolute risk of life-threatening cardiac events in long QT syndrome patients
por: Wang, Meng, et al.
Publicado: (2022)

Intrinsic antitachycardia pacing for patients with multiple ventricular tachycardias
por: Okubo, Kenji, et al.
Publicado: (2022)

Genetic variant annotation scores in congenital long QT syndrome
por: Younis, Arwa, et al.
Publicado: (2023)

Automatic adjustment of ventricular antitachycardia pacing and individualized device therapy
por: Tripathi, Rajiv, et al.
Publicado: (2021)

Termination of Ventricular Tachycardia with Antitachycardia Pacing after Ineffective Shock Therapy in an ICD Recipient with Hypertrophic Cardiomyopathy
por: Margos, Panagiotis N, et al.
Publicado: (2009)

Effective Antitachycardia Therapy by Temporary External Defibrillator Utilized as Bridge to Reimplantation
por: Falasconi, Giulio, et al.
Publicado: (2022)

Reactive atrial‐based antitachycardia pacing therapy reduces atrial tachyarrhythmias
por: Crossley, George H., et al.
Publicado: (2019)

Effectiveness of changing conventional implantable cardioverter-defibrillator settings to intrinsic antitachycardia pacing–like settings in the treatment of ventricular tachycardia in patients with cardiac failure
por: Tachibana, Motomi, et al.
Publicado: (2022)

Atrial Antitachycardia Pacing in Complex Congenital Heart Disease: A Case Series
por: Kramer, Collin C., et al.
Publicado: (2018)

The common apolipoprotein A-1 polymorphism −75A>G is associated with ethnic differences in recurrent coronary events after recovery from an acute myocardial infarction
por: Block, Robert, et al.
Publicado: (2009)

Inadvertent Disabling of Implantable Cardiac Defibrillator Antitachycardia Therapies Following Breast Reconstructive Surgery
por: Skaff, Paulina R., et al.
Publicado: (2020)

Dual chamber pacing mode in an atrial antitachycardia pacing device without a ventricular lead – A necessary evil
por: Noheria, Amit, et al.
Publicado: (2015)

CHA(2)DS(2)‐VASc Score and the Risk of Ventricular Tachyarrhythmic Events and Mortality in MADIT‐CRT
por: Nof, Eyal, et al.
Publicado: (2019)

Cost-effectiveness analysis of cardiac implantable electronic devices with reactive atrial-based antitachycardia pacing
por: Noda, Takashi, et al.
Publicado: (2023)

Combined effects of high atrial septal pacing and reactive atrial antitachycardia pacing for reducing atrial fibrillation in sick sinus syndrome
por: Sumiyoshi, Hironobu, et al.
Publicado: (2023)

Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhythmias: the MINERVA randomized multicentre international trial
por: Boriani, Giuseppe, et al.
Publicado: (2014)

Predictive value of global longitudinal strain by left ventricular ejection fraction
por: Medvedofsky, Diego, et al.
Publicado: (2023)

What factors lead to the acceleration of ventricular tachycardia during antitachycardia pacing?—Results from over 1000 episodes
por: Fang, Yin, et al.
Publicado: (2017)

An appropriate shock of the wearable cardioverter-defibrillator in an outpatient setting
por: Kishihara, Jun, et al.
Publicado: (2016)

Subcutaneous Implantable Cardioverter-Defibrillator Shock: Appropriate or Inappropriate?
por: Ip, James E.
Publicado: (2017)

High shocking and pacing impedances due to defibrillation lead calcification
por: Hauser, Robert G., et al.
Publicado: (2019)

Implantable cardioverter defibrillator for primary prevention in patients with non-ischemic cardiomyopathy in the era of novel therapeutic agents- meta-analysis
por: Kolben, Yotam, et al.
Publicado: (2023)

Left-to-right atrioventricular activation delay, a novel measure of AV-conduction, predicts clinical outcomes in non-LBBB patients
por: Beierle, A S, et al.
Publicado: (2023)

AnaLysIs of Both sex and device specific factoRs on outcomes in pAtients with non-ischemic cardiomyopathy (BIO-LIBRA): Design and clinical protocol
por: Kutyifa, Valentina, et al.
Publicado: (2020)

ECG Marker of Adverse Electrical Remodeling Post-Myocardial Infarction Predicts Outcomes in MADIT II Study
por: Tereshchenko, Larisa G., et al.
Publicado: (2012)

Confirm Rx insertable cardiac monitor for primary atrial fibrillation detection in high‐risk heart failure patients (Confirm‐AF trial)
por: Aktas, Mehmet K., et al.
Publicado: (2022)

Heart defibrillation: relationship between pacing threshold and defibrillation probability
por: Antoneli, Priscila C., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b3vh976aacc03cuo9l4o1e0jr7